Combination immunotherapy with nivolumab and ipilimumab provided intracranial and extracranial responses for patients with melanoma and brain metastases.
Nivolumab alone or in combination with ipilimumab were reported to show activity in patients with melanoma and asymptomatic brain metastases.
After looking at 8 short-term endpoints based on PSA and CTCs, absence of tumor cells at week 13 was considered the best predictor of overall survival.
When combined with an aromatase inhibitor, dual HER2 blockade shows superior PFS compared with lapatinib or trastuzumab alone in some women with breast cancer.
The antibody drug conjugate, T-DM1, when used alone or in combination with pertuzumab, did not significantly improve overall survival compared with trastuzumab and a taxane.
Evidence suggests that combining palbociclib with endocrine therapy can reverse acquired resistance to endocrine therapy in breast cancer.
A study showed that symptom monitoring by integrating electronic patient-reported outcomes into clinical practice vs usual care extended OS by more than 5 months.
Data from PALOMA-1/TRIO-18 showed that combining palbociclib and letrozole did not significantly improve survival compared with letrozole alone among patients with breast cancer.
Patients with breast cancer who progress on endocrine therapy and are then treated with abemaciclib and fulvestrant have a 45% decreased risk for progression.
Vemurafenib improves outcomes among patients with non-small cell lung cancer with a BRAFV600 mutation.
Please login or register first to view this content.
